REGISTER
Gene Therapy Restores Hearing in OTOF Deafness
A China-led Nature study reports durable hearing gains after one-time OTOF gene therapy. In 42 patients followed for up to 2.5 years, 90% showed improvement.

A new clinical study led by Chinese researchers is redefining the therapeutic boundary for congenital deafness: 90% of patients with congenital hearing loss regained hearing after gene therapy.

On April 22, Nature published a landmark clinical study led by Prof. Yilai Shu of the Eye, Ear, Nose and Throat Hospital of Fudan University. It is the largest clinical study to date in the field of gene therapy for deafness, the longest in follow-up, and the first complete clinical trial report in this field to appear in Nature.

Hearing improved in 90% of patients

About 26 million people worldwide live with congenital deafness, and China records roughly 20,000 to 30,000 new hearing-impaired newborns each year. Mutations in OTOF are a common cause of hereditary congenital deafness, accounting for about 2% to 8% of hereditary deafness cases.

OTOF encodes otoferlin, a key protein required for transmitting sound signals from inner-ear sensory cells to the brain. When OTOF is mutated, the signal cannot be delivered, leaving patients with severe to profound deafness even when loud sounds are produced nearby.

The gene therapy co-developed by Prof. Shu delivers a normal copy of OTOF into inner-ear cells, enabling them to produce otoferlin again and restore the ability to transmit auditory signals.

In January 2024, the team reported unilateral treatment results in the Lancet for the first six children; five showed marked hearing improvement. In June 2024, the team reported preliminary bilateral treatment data in five children, showing that treatment of both ears could further restore sound localization.

Those early studies were limited by sample size and by uncertainty over whether the inserted gene could produce stable long-term benefit. The Nature study addressed both questions.

The study was led by the Eye, Ear, Nose and Throat Hospital of Fudan University together with seven other tertiary hospitals across China. It enrolled 42 patients aged 9 months to 32 years. The team used a dual-vector delivery strategy, splitting the large OTOF sequence into two vectors for injection into the inner ear, where the complete functional gene is reassembled inside cells.

The entire treatment requires only one injection, with the total volume roughly equal to a drop of water.

Results showed hearing improvement in 90% of treated patients. Before treatment, auditory brainstem response thresholds were generally above 97 dB, indicating severe to profound deafness. After treatment, the mean threshold gradually fell to about 42 dB, roughly the level needed to hear everyday conversation.

Among patients followed for as long as 2.5 years, 100% of responders recovered enough hearing to understand daily speech, 57% could identify soft background sounds at library-level intensity, and 43% could hear whispers.

Adult patients also benefited

A particularly important finding was that the treatment window may extend beyond early childhood. Previous trials of gene therapy for deafness enrolled almost exclusively children, because older patients were thought to face higher risks of hair-cell degeneration and lower auditory cortical plasticity.

In this study, the treated age range extended to 32 years, and adults also benefited. Of three patients older than 20 years, two had clear hearing improvement. A 32-year-old patient showed a 27 dB nHL improvement in ABR threshold at one year, and a 20-year-old patient improved by 20 dB nHL at 13 weeks.

The finding supports the clinical value of gene therapy for adults with OTOF-related deafness, a population previously regarded as having missed the therapeutic window. Younger patients still showed advantages in speech perception recovery, consistent with language-center development, but hearing recovery alone has independent clinical value for older patients by improving environmental awareness, danger recognition, and interpersonal response.

The researchers also identified distortion product otoacoustic emissions, or DPOAE, as a practical predictor of response. Because DPOAE reflects outer hair cell function, it can indirectly indicate whether the inner ear hardware remains intact. Patients with better DPOAE results before treatment tended to have more pronounced hearing recovery after treatment.

A new era for hereditary deafness

After the study was released, co-corresponding author Prof. Zheng-Yi Chen of Harvard Medical School said in media interviews that seeing patients go from complete deafness to hearing sound was extraordinary and represented the first truly new treatment option in the field of hearing loss.

More than 200 genes associated with hearing loss have been identified. OTOF became an early breakthrough target because its disease mechanism is clear and because OTOF mutations typically do not destroy hair cells or inner-ear structure, leaving a repair window for gene therapy.

In this sense, OTOF is an ideal model for validating gene therapy in deafness. Its success offers a replicable path for treating other deafness genes.

At least five teams worldwide are now advancing clinical trials targeting OTOF. In October 2025, Prof. Shu and 46 multidisciplinary experts issued the first international expert consensus on gene therapy for hereditary deafness, an important step toward standardizing the field.

Research targeting more common genes such as GJB2 and TMC1 has also shown encouraging progress in animal models. In August 2024, Prof. Shu's team reported in Nature Biomedical Engineering that base editing restored hearing in OTOF deafness mouse models for up to 1.5 years, suggesting a next-generation therapeutic strategy.

For decades, congenital deafness management relied mainly on cochlear implants and hearing aids. Implants provide electronic replacement, and hearing aids amplify sound, but neither corrects the underlying genetic defect. Gene therapy works by replacing what is missing: a functional gene copy delivered directly to inner-ear cells so that they can produce the needed protein and restore a natural auditory pathway.

Prof. Shu has said that more researchers and more orderly competition will benefit the entire field. Gene therapy is a high-technology area with long development cycles and large investment needs, but it addresses difficult, disabling, and sometimes life-altering diseases.

0
0
Loading